Menveo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of national immunization schedules, historical outbreaks of meningococcal disease, advancements in conjugate vaccine technology, increased awareness of vaccine-preventable diseases, global vaccination initiatives.

The growth in the forecast period can be attributed to growing investments in vaccine innovation, rising focus on outbreak prevention, expansion of adult and adolescent immunization coverage, increasing travel-related vaccination demand, strengthening of public health infrastructure. Major trends in the forecast period include increasing adoption of conjugate vaccines, rising focus on preventive immunization programs, growing demand for adolescent and travel vaccination, expansion of multivalent vaccine coverage, enhanced emphasis on public health preparedness.

The rising prevalence of meningitis is expected to drive the growth of the Menveo market in the coming years. Meningitis is an infection that causes inflammation of the protective membranes surrounding the brain and spinal cord, often triggered by viral, bacterial, or fungal pathogens. The increase in meningitis cases is largely driven by factors such as growing global mobility and weakened immune systems, which elevate the risk of disease transmission. Menveo supports public health efforts by offering protection against multiple strains of Neisseria meningitidis, enabling early prevention, reducing disease spread, and lowering the burden of invasive meningococcal infections. For example, in October 2025, the UK Health Security Agency, a UK-based government agency, reported that 378 invasive meningococcal disease (IMD) cases were confirmed in 2024-25. Therefore, the increasing prevalence of meningitis is driving the growth of the Menveo market.

The global expansion of healthcare infrastructure is also expected to drive the growth of the Menveo market. Healthcare infrastructure encompasses the physical and organizational structures, facilities, resources, and systems needed to deliver healthcare services. Factors such as the aging global population, the rise in chronic diseases, and technological advancements are contributing to the expansion of healthcare infrastructure. Menveo, as a meningococcal vaccine, benefits from this growth by being included in vaccination programs across clinics, hospitals, and public health initiatives. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, a significant rise compared to the 0.9% growth in 2022. Therefore, the global expansion of healthcare infrastructure is contributing to the growth of the Menveo market.

A key trend in the Menveo market is the development of innovative vaccine formulations, such as single-vial, fully liquid formulations, to improve convenience, stability, and simplify vaccine administration. Single-vial, fully liquid formulations refer to vaccines that are pre-mixed and packaged in a single vial, with the active ingredients dissolved in liquid form, making them ready for immediate use without the need for reconstitution. For example, in November 2024, GlaxoSmithKline (GSK) plc, a UK-based pharmaceutical company, received approval from the European Commission (EC) for a new presentation of its meningococcal vaccine, Menveo, for active immunization against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y. The approval includes a new single-vial, fully liquid formulation, eliminating the need for reconstitution before use. The vaccine is now licensed for use in children aged two years and older, adolescents, and adults in the European Union.

Major companies operating in the menveo market are GlaxoSmithKline (GSK) Plc.

North America was the largest region in the menveo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menveo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the menveo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the menveo market by increasing costs of imported vaccine antigens, adjuvants, sterile vials, syringes, and cold-chain distribution materials used in vaccine manufacturing and delivery. Public immunization programs in North America and Europe are most affected due to dependence on globally sourced vaccine inputs, while emerging markets face pricing pressures on vaccine procurement. These tariffs can impact large-scale vaccination budgets and supply timelines. However, they are also encouraging regional vaccine manufacturing, domestic fill-and-finish capabilities, and long-term supply security for essential immunization products.

The menveo market research report is one of a series of new reports that provides menveo market statistics, including menveo industry global market size, regional shares, competitors with a menveo market share, detailed menveo market segments, market trends and opportunities, and any further data you may need to thrive in the menveo industry. This menveo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Menveo is a meningococcal vaccine that provides protection against infections caused by Neisseria meningitidis. It targets serogroups A, C, W, and Y, which are responsible for causing meningitis and bloodstream infections. The vaccine is recommended for adolescents, young adults, and individuals at higher risk of contracting meningococcal disease.

The main types of Menveo include conjugate vaccines and combination vaccines. A conjugate vaccine combines a bacterial protein with a polysaccharide (sugar molecule) to enhance the immune response, helping the immune system recognize and attack the bacteria more effectively. Menveo is indicated for a variety of purposes, including meningococcal disease prevention, routine immunization, outbreak control, and travel vaccination. It is used across different age groups, including infants and young children, adolescents, adults, and older adults. End users of Menveo include hospitals, vaccination clinics, travel clinics, academic and research institutions, as well as military and government facilities.

The menveo market consists of sales of prefilled syringes, powders for suspension, combination vaccines, booster doses, and single-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.